EIT Health Germany European Health Catapult Regional Finalists and Headstart Awards Final Pitches and Awards Ceremony

Transcription

1 EIT Health Germany 2018 Regional Finalists and Final Pitches and Awards Ceremony

2 Agenda 09:00-10:00 Registration, Embarkation & Morning Coffee 10:00-10:15 Departure & Welcome Notes 10:15-11:00 Pitch Round I, - 11:00-11:20 Coffee Break 11:20-12:50 Pitch Round II & III, - & 12:50-13:00 Group Picture 13:00-14:00 Lunch & Matchmaking 14:00-15:30 Pitch Round for EIT Health 2018 Headstart Funding Start-ups 15:30-17:00 Afternoon Tea & Headstart Matchmaking 17:00-18:00 Award Ceremony followed by Networking Drinks approx. 18:00 Arrival at the Pier & Disembarkation Herzlich Willkommen, A Very Warm Welcome I am so very glad you are able to join us aboard the Königin Silvia for the 3rd edition of EIT Health Germany s Ship for Health Innovation Pitches (SHIP) today, and hope you re as excited as I am to hear our 30 regional finalists pitch their newest healthcare innovations to our expert jury. Approximately half of the teams presenting today are competing for one of the six entry tickets EIT Health Germany holds to EIT Health s (EHC) programme. Those passing today s regional pre-selection will be given the opportunity to perfect their pitch through intensive coaching by pitch coaches from Silicon Valley, to present their company in front of experts and international investors during the European semi-finals taking place in autumn, and ultimately have the chance to be showcased at EIT Health s Annual Summit in front of 500+ representatives of our 140+ partner organisations. The other half of the teams is vying for one of EIT Health Germany s 2018 Headstart Awards, which are valued at 50,000, and of which we will be awarding five today. The EIT Health are part of EIT Health s extensive portfolio of support programmes for emerging companies and SMEs from across Europe. The purpose of these awards is to support start-ups/smes in realising their next steps towards the market and shorten the time-to-market for their innovative products and services It s going to be a fantastic day today, so make sure to tag us (#SHIP2018) on social media (@EIT_health_de as you tell the world about it. Please make use of the opportunity to mingle with the teams during the networking session and do not forget to enjoy the view along the route! Good luck to our teams! Toi, toi, toi! Yours truthfully, Dr. Katharina Ladewig Managing Director, EIT Health Germany Agenda

3 EUROPEAN HEALTH CATAPULT Regional Finalists 2018

4 Aquarray Aquarray s proprietary Droplet Microarray (DMA) is a product innovation which enables novel highly miniaturized biochemical and cell based screenings. The DMA is saving costs by miniaturization while both, accelerating screening and increasing the predictivity of screening results by enabling physiologically more relevant screening models. Cell screening is an essential technology for fundamental life science research, is of high relevance for personalized drug screenings and is an integral part of every drug discovery campaign. The market of cell based screening in 2018 has a volume of USD 15.1 billion, the market is growing at a CAGR of 8.0%. Aquarray addresses the submarkets Consumables and Reagents with a volume of USD 5.3 billion. Aquarray products meet the growing demand for primary and stem cell screenings addressing three customer segments: fundamental life sciences, personalized medicine and industrial drug discovery. The technology transfer project Aquarray is funded by the EXIST Forschungstransfer program, an ERC-Proof-of-Concept grant and located at the KIT, which allows to access a first class R&D infrastructure. The founders team combines research, industrial and commercial expertise, bringing together highly qualified specialists with many years of experience. Due to the ongoing EXIST funding, the salaries of the core entrepreneurial team are covered until Q4/2019. The goal of the EXIST project is to scale the production capacity. For further product development, certifications, building up additional competences in the team and implementing a standardized, automated and certified production with an output of units per month by 2023, Aquarray is looking for venture capital. mk2 Biotechnologies mk2 Biotechnologies has developed a revolutionizing bio-based synthesis technology which allows the scalable production of high purity peptides with arbitrary chemical and physical properties. While conventional synthesis methods are strong in the supply of simple peptides, complex peptides with more powerful properties like antimicrobial, anti-fungicidal, cosmetical and pharmacological activities are not easily accessible due to technological inhibition. Being the bottleneck in conventional methods, the purification (usually via HPLC) can cause more than 80% of the product cost. Since all applications demand a certain quality and purity, no synthesis technology was yet able to fulfill the technical and particularly economical requirements of mass applications like agriculture and cosmetics. mk2 Biotechnologies is instead able to provide biologically produced authentic peptide sequences without any technical limitations. To the best of our knowledge, this is the first method, which is in principal fully scalable and automatable and produces only small amounts of non-toxic recyclable waste. Opposite to conventional methods, mk2 Biotechnologies uses an innovative purification method which, in combination with high synthesis yields, can lead to significant cost reduction by orders of magnitude already on the lab scale. Since there is no bottleneck in the biological synthesis route, the synthesis is fully scalable, which can bring the production cost down to mass market needs. Although being in the very early stage, mk2 Biotechnologies has already achieved severe technological progress, implying that complex peptides might soon be applied as substitutes for chemical crop protectors, antibiotics, drugs, skin and hair revitalizers and many more. Dr. Simon Widmaier simon.widmaier@kit.edu Konstantinos Antonopoulos, CEO konstantinos.antonopoulos@mk2.bio 6 7

5 Pharmgenomics ColoAlert is the first affordable DNA-based colorectal cancer stool test. A study confirmed a leading 85% sensitivity for its combination of 3 genetic biomarkers with the established FIT while easily meeting the recommended specificity of 90%. Mr. Moritz Eidens, M.Sc. Biomedicine, CEO Mr. Philipp Freese, Diploma Business Administration, CEO philipp.freese@pharmgenomics.de Dentavenir GmbH & Co. KG Dentavenir GmbH & Co. KG is manufacturing 3D printed appliances that radically improve the design and fabrication processes, thus rendering personalized medicine in the field of orthodontics a reality. More specifically, removable orthodontic devices, such as, for example, dental braces, are worldwide manually manufactured with manual processing often resulting in poorly fitting devices. Our patent-pending process enables the digital design and manufacturing of removable appliances. First, the practitioner digitally scans the patient s oral area with an intra-oral scanner. The scanned digital data are then sent to Dentavenir, edited and 3D printed in an error-free process that results in an end-product that perfectly fits the oral cavity of the patient. Due to the high precision, the appliances can be worn without metal aligners, are very comfortable and almost invisible. This results in longer Markus Utomo, CTO Dentavenir mu@dentavenir.de periods of wearing, thus shortening the treatment time. The benefits of our digitally produced orthodontic devices go beyond the practical aspects. Indeed, our digital, personalized approach also revolutionizes the aesthetics of orthodontics by allowing for the incorporation of fully colored, large-scaled digital images in the dental devises. Remarkably, patients can choose their favorite image via app being thus directly involved in their treatment. These innovative aspects of digital, 3D printed orthodontic devices lead to a vastly increased compliance, especially among small children, who constitute the majority of orthodontic patients. 8 9

6 Kaia Health twitter.com/kaiahealth In 2018, Kaia Health released its second therapy, Kaia COPD. The WHO predicts Chronic Obstructive Pulmonary Disease (COPD) to be the third leading cause of death by This respiratory disease affects up to 15% of the adult population in developed countries and is traditionally treated with medication-based therapy. Newer research however emphasizes the growing evidence for non-pharmacological approaches such as pulmonary rehabilitation (PR). PR is a multidisciplinary intervention combining physical therapy with psychosocial interventions and patient education. Kaia digitized this therapy for the first time, delivering it to patients on the smartphone. Even though international guidelines clearly suggest PR for any symptomatic COPD patient, only a fraction of patients who could benefit from the therapy are currently being referred to it. In Germany only around PRs are performed each year while over five million patients would be eligible. To address this gap, Kaia teamed up with leading providers and researchers of PR and carefully digitized the key elements of the therapy to make it accessible in an easy-to-use, affordable and comprehensive smartphone application. In this process, Kaia benefited from the insights gained by analyzing over users of the Kaia backpain app which was released in Even though the app has only been in the market since February, over COPD patients are using it; making Kaia the market leader. The product is CE-certified and a first observational study, presented at the European Telemedicine Conference in May 2018, showed significant improvements on clinically relevant self-reported patient outcomes. Memocorby twitter.com/memocorby facebook.com/memocorbysystems Memocorby is a neuroscientific-based, digital, multi-sensory tool for re-learning language for stroke patients or children with language problems, and for patients who suffer from dementia to maintain language, in a rapidly growing international healthcare market. (Re-) Learn language with Memocorby. Our mission is to help children and adults with speech- and language problems. We developed a multi-sensory therapy and learning tool to (re-) learn language for the speech pathology market which the patient can use independently at home but under supervision of the therapist in any chosen language. How it works: Memocorby consists of up to 10 digital cubes each equipped with a graphical TFT-display, a tablet computer and an app uniting visual, auditive, haptic and emotional learning in one dedicated tool. By stimulating all five senses simultaneously the speech therapy technology presented by Memocorby is by far superior to conventional approaches. Memocorby also offers advantages to the therapist. For example, the therapist can select the language on the cube, thus allowing for treatment of the patient in his/her first language, or sending new therapies remotely to the patient so he/she can learn at home yet under supervision of the therapist. The Memocorby cubes communicate wirelessly with an app. As soon as the app has started the patients are able to hear the work task and see the answer(s) on the cube s display. One task would be to lift the correct cube. As soon as patients have chosen the appropriate cube they immediately hear the correct word/name of the picture/sound being pronounced and receive an auditive stimulus. Simultaneously the learner gets a haptic stimulus by lifting the cube. Memocorby combines the advantage of individualised personal therapy with new digital e-health technology. Jonas Duss, Co-Head of Drug Development jonas@kaia-health.com Dr. Elisabeth Dokalik-Jonak, CEO of Memocorby elisabeth.dokalik@memocorby.com 10 11

7 Mindpax twitter.com/mindpax Mindpax is a digital medicine company that is building predictive algorithms for severe psychiatric diseases. Mindpax had developed long-term monitoring system for patients suffering from schizophrenia and bipolar disorder spectrum. The system currently monitors schizophrenia patients in clinical setting and bipolar disorder spectrum patients in clinical trial developing the relapse predicting algorithm. The technology is based on a longitudinal monitoring of sleep, physical activity (sensor) and validated subjective questionnaires. Combination of these three data sources will enable us to create the digital biomarker predicting relapses. NMP addresses the market of unmet needs for severe psychiatric disorders relapse prediction and decrease of hospitalization needs for these patients thus saving substantial costs to the healthcare providers. Products Pavel Nevicky, CEO project/company management pavel.nevicky@mindpax.me Sona Sikorova, COO clinical studies management Relapse Predicting Algorithm for Schizophrenia (ITAREPS) Neuropsychiatry Monitoring Platform (NMP) Mindpax Digital Neuropsychiatry Biomarker for Relapse and Mood Change Prediction (MDNB) Mindpax Bipolar Mood Self-Assessment Questionnaire Sleepiz AG Sleepiz AG is a Zurich based award-winning Med-tech start-up founded by graduates from ETH Zurich and the University of St. Gallen (HSG), backed by leading sleep specialists in Switzerland. 30% of the world population suffers from sleep disorders. Sleep apnea is the most serious sleep disorder whereby one stops breathing frequently while asleep, it has a global prevalence of 1 billion - yet more than 80% of these cases are not diagnosed! If left untreated, it doubles the risk for sudden cardiac death, stroke, increases the risk for cardiovascular mortality fivefold, and leads to dementia, traffic accidents, and productivity losses. The current healthcare system is not equipped to handle such an influx of cases due to outdated screening and diagnosis technologies. For example, the state of the art requires overnight hospitalization, full-time supervision by a technician, and the attachment of more than 30 cables. As a result, doctors incur a huge time and cost burden in conducting such tests and are looking for more efficient screening solutions without having to compromise for data accuracy and reliability. Mr. Max Sieghold, Co-Founder and Chief Financial Officer (CFO) max.sieghold@sleepiz.com Sleepiz has developed a revolutionary sleep disorder screening device. By using wireless technology, the device can measure human vital signs at medical accuracy without touching the patient - enabling non-contact clinical grade home diagnosis of sleep apnea. To date Sleepiz has proven the technology in a clinical context and is currently in the process of obtaining the necessary medical approvals. Please contact Sleepiz for more information and support next generation home-diagnostics! 12 13

8 Anvajo Anvajo has developed a small Point-of-caredevice based on an optical sensors technology providing immediate results at lab-grade accuracy with only little amounts of blood. The first available diagnostic test is a CRP and WBC test which focuses on the differentiation between viral and bacterial infections to minimize unnecessary prescription of antibiotics. The technology is based on a small optical sensor solution consisting of a miniaturized spectrometer and microscope and allows to decode a variety of different liquids. The respective liquid is applied to a microfluidic test chip or cuvette which are disposable sample carriers for automatic sample preparation and analyses in the Minilab device. The solution can be applied to a broader business scope such as analytics of food, animal feed and/or environmental. Anvajo s focus is on the development of a platform solution, which can be used e.g. in clinical diagnostics to examine blood, urine, sperm and others directly at the point-of-need. Quantitative results are available within seconds or minutes depending on the fluid being decoded. Performance and accuracy of our patented tech core components are comparable with equipment in central laboratories. Digital interfaces allow simple connectivity to telemedical networks and applications. Medical Magnesium Medical Magnesium is a medtech start-up that revolutionizes modern patient care by developing and marketing bioabsorbable orthopedic implants made of magnesium. The current standard of care to cure bone fractures requires a removal surgery of the permanent implant material. Patients inevitably suffer from unnecessary pain, longer healing time, high risk of infection causing increased healthcare costs. Especially more complex fractures such as broken ankles or collar bones require a removal of the implant in a painful second surgery. Medical Magnesium has created a new class of orthopedic implants that eliminate the need for a removal surgery, as they absorb in a controlled manner. To apply a single surgery therapy to more complex fractures a bioabsorbable implant must prove a certain mechanical strength holding the bone fragments in place allowing them to merge again. Medical Magnesium s platform material technology combines both desired properties, mechanical strength and a controlled degradation. By applying an innovative ceramic coating Medical Magnesium enables control of the degradation behavior of the implant, which is the crucial factor in magnesium implant technology. The implant remains permanently stable until the mechanical integrity of the fractured bone is restored. Thereby the implant will degrade physiologically while equivalent new bone tissue is formed. The technology platform has demonstrated its medical performance in two pre-clinical animal models as required for class III medical devices. Together with leading users from orthopedics and trauma surgery the team gained expertise in clinical approval to bring its first product, an implant screw, to market in Hans-Gert Stuke, Managing Director hans-gert.stuke@anvajo.com Florian Coppers, CEO coppers@medical-magnesium.com 14 15

9 Ormosys Ormosys is a holistic dynamic body analysis system. The results are usable for doctors, podiatrist and chiropractors for diagnostic, therapy - treatment plan and for prescription. the report is also usable for manufacturing holistic - dynamic - customized orthotics and sandals. Intelligence derived from combining human gait analysis and other holistic and dynamic measurements transform ordinary people into extraordinary performers. SensArs twitter.com/sensarsnpt SensArs Neuroprosthetics is an EPFL spin-off that was founded in Saint-Sulpice in 2014 by Francesco Petrini and Stanisa Raspopovic, two researchers of EPFL, and Silvestro Micera, professor of EPFL and Scuola Superiore Sant Anna (Italy). Since its creation SensArs has raised more than CHF in non-dilutive grants, and has filed two patent applications. Thanks to this support, SensArs has developed SENSY, unique worldwide device to restore sensory feedback to lower limb amputees from their prosthesis. SensArs has also conducted a pilot trial with three lower limb amputees, preliminarily proving that SENSY reduces the risk of falls, increases the perception of the prosthesis as part of the body, and diminishes phantom limb pain. Lower limb amputees are about 4 million only in USA and Europe. SensArs is now organizing a series A fund raising of 6 million. This money is needed to develop the final version of SENSY, and to run a clinical trial with 40 patients to gather CE mark and start commercialization. Mr. Fatmir Langmeier, CEO fl@ormosys.com Francesco Maria Petrini, CEO and cofounder of SensArs francesco.petrini86@gmail.com 16 17

10 TherapySelect Targeted drugs are the new promising drug alternatives for cancer. However only 25% of cancer patients respond to drug therapy, even to these new targeted drugs. Unfortunately, the costs are extremely high and the drug efficacy varies tremendously. The current molecular-based diagnostics are not sufficient to find the best drugs for an individual patient. TherapySelect offers a commercial diagnostic product, whose technology can be used to solve the problem. The product is called CTR-Test (Chemotherapy-Resistance-Test). It can measure the efficacy of chemotherapeutic drugs to find the best chemotherapy option for an individual cancer patient. The test is based on a cell technology which uses freshly isolated, living tumor samples from patients. These samples are prepared as 3D-microtumor (patient derived organoid) structures. The idea is to apply the technology to the targeted drugs. Up to now there exist 32 approved targeted drugs, which could be measurable by the CTR-Test technology. The project is demanding since 1. up till now no cell-based technology was applied as a companion diagnostic tool and 2. the targeted drugs behave differently in the test system in terms of efficacy profiles. Our team has the know how and experience to successfully use our cell technology for these drugs. Our new diagnostic using the CTR-Test technology can be the universal companion diagnostic for all targeted drugs directly acting on cancer cells since we are able to reach a prediction probability above 90%. The commercialization of the new diagnostic shall be realized via a test kit model. Dr. Frank Kischkel, Managing Director frank.kischkel@therapyselect.de 18 19

11 THE JURY / JUDGES Biography: Sylke was born and raised in Chemnitz, Germany and London, UK. During her undergraduate studies at ETH Zurich and PhD studies at EPF Lausanne, she co-authored publications in Nature Methods and Nature Cell Biology. Following her doctoral studies, Sylke co-founded the Swiss life science company SUN bioscience. Sylke was Sylke Hoehnel Company: SUN bioscience Job title: CEO & Co-founder named to Forbes Under 30 Europe list in the category Science and Health Care and she holds several awards including the 2016 Founder. org Silicon Valley Accelerator, the 2017 EIT Health Catapult First Prize for the Category Biotech and the 2018 W.A. de Vigier award

12 Biography: Andreas Huber is Scientific Director Life Science and Senior Investment Manager at Bayern Kapital. His background is in biology which he studied at the Technical (TUM) and the Ludwig Maximilians University (LMU) in Munich. Additionally, he obtained a degree in Business Administration and Economics. Prior to Bayern Kapital he worked as an Analyst for a Munich-based Venture Capital company and as a Business Development Manager with a Medtech-Software-Start-up. Bayern Kapital is a Andreas Huber Company: Bayern Kapital GmbH Job title: Scientific Director Life Science; Senior-Beteiligungsmanager Venture Capital company, founded in 1995 by the Bavarian government and invests -always together with other investors- in young, innovative hightech companies in Bavaria. Since 1995 Bayern Kapital has invested over 250m EUR in more than 250 companies, with a focus on Life Science and IT/internet start-ups. Bayern Kapital currently has 325m EUR under management and received new funding including the 100 meur-growth Fund ( Wachstumsfonds ). Biography: Tim founded his first company enmodes GmbH in He built it up from scratch, starting with one computer in his living room, to a profitable service company with a two-digit annual growth rate. enmodes has helped medical device companies throughout the world on their path to market. Among the list of clients are new Start-Ups as Tim Kaufmann Company: Enmodes GmbH Job title: CEO well as world leaders in medical device technology. enmodes has fostered over 20 international collaborations in Europe, US and Asia. Within the past years, enmodes has also become a platform to develop cutting-edge technologies such as RAS-Q: the world s first longterm respiratory assist device to treat patients with severe lung diseases

13 Biography: Birgit has been actively engaged in establishing technology transfer at the European Molecular Biology Laboratory (EMBL) more than 17 years ago and has since held various positions at EMBL s technology transfer arm, EMBLEM. She is currently responsible for business development at the European Bioinformatics Institute (EMBL-EBI) and business development lead for Open Targets, a public private partnership with GSK, Biogen, Takeda, Celgene and the Wellcome Sanger Institute. Birgit has been engaged in managing and Dr. Birgit Kerber Company: EMBL Enterprise Management Technology Transfer GmbH Job title: Head Innovation and Translation EMBL-EBI; Business Development Lead Open Targets; Business Development Manager licensing intellectual property with biotech and large pharma companies as customers as well as starting companies out of EMBL. She holds a diploma in biology from Philipps-University Marburg, did her PhD work at the Max-Planck-Institute for biophysical chemistry in Goettingen and a postdoc at EMBL Heidelberg. She is a member of BIO Deutschland and the Licensing Executives Society as well as an alumna of St Gallen Business School, CEIPI, Boehringer Ingelheim Fonds, DFG and EMBO. Biography: For twenty years Malaika has been working as a life science company builder and consultant in Germany and the US. The main projects and companies are located in the field of sleep disorders (TNI medical GmbH), breathing (respeq Inc.) and neurological implants (neuroloop GmbH). Malaika Lauk Baden-Württemberg: connected e.v.-(bwcon, Network Management Healthcare) Dr. Lauk Management Consultants (Consultant) For bwcon Malaika connects science, business and B&B. In the healthcare sector, bwcon wants to give its members an advantage in competition and the possibility to develop new business models. She helps with funding and organizing matchmaking for start-ups, SMEs and large scale enterprises while working with the leading business initiative for the promotion of the hightech sectors in Baden-Württemberg

14 Friedrich (Fritz) Richter, Ph.D. Biography: Dr. Richter is currently Managing Director of the BioRN network, one of the leading biotech clusters in Germany and Europe. Prior to this position which he holds since 2017 Dr. Richter spent 31 years in various R & D leadership and executive positions in the global pharmaceutical industry. Company: BioRN Job title: Managing Director He started his career as a formulation and drug delivery scientist at Sandoz AG in Basle/Switzerland. Further positions were Head of Pharmaceutical & Analytical Development at Novartis AG, Vice President of Preclinical Development at BASF Pharma/Germany and Vice President of Preclinical Development at Abbott Laboratories/Chicago/ USA. In 2007 Dr. Richter became Vice President of Drug Product Development at Abbott and also General Manager of Abbott Germany. He was moved in these positions to the newly formed company AbbVie when Abbott spun off its research based pharmaceutical business 2013 until his retirement Dr.Richter studied Pharmacy at the University of Tuebingen/Germany and got his Ph.D. in Pharmaceutical Chemistry from the University of Freiburg/ Germany. Biography: Thomas York Götz Thomas York Götz has more than 20 years of experience in start-ups, family owned companies, private equity owned companies and blue chip corporates. Thomas is an expert in evaluating companies, building teams, entrepreneurship especially connecting marketing and finance. Thomas connected with Weigel Corporate Finance network in 2015 after working in international firms like Univar EMEA, Vodafone, Wunderman and family owned businesses like Nordmann, Rassman Group. In all companies marketing & sales, change Company: Weigel Corporate Finance Job title: MBA management and financial played a major role next to the development of the employees. The last years Thomas worked as a coach and jury member for the European Venture Contest, as jury member and mentor for the startupbootcamp smart materials, industry expert and evaluator for EIT Health. Thomas is member of the foundation for the promotion of the bio-industry in North-Rhine Westphalia and the association BioRiver Life-sciences in the Rhineland e.v

15 EIT HEALTH HEADSTART AWARDS Finalists EIT Health Germany 2018

16 Germany Avalanche Avalanche is developing a 3D recognition system to replace manual documentation of deployed implants during surgical operations. A modern trauma clinics deploys different implant kits, some of which consist of parts. The existing protocol is complex, time consuming, error prone, causes delays during the operation, and brings complication risks for the patients. There are cases, when a patient needs to be kept anesthetized while a missing implant part is being delivered by taxi from another clinic. Our 3D recognition technique works directly in the operating theatre. It will recognize the implants directly on the sterile side. Our unique set of algorithms allows for recognition of implant parts across different implant kits. This technology software has become suitable for affordable hardware only about 6 months ago. Our product will make use of this fact and create an innovative and cost effective solution for clinics which increases safety during operations. Prospective customers are all the customers of implant manufacturers worldwide, i.e. hospitals, emergency services and other medical care facilities. Avalanche is a medical innovation startup from Southern Germany, focused on 3D applications in trauma surgery. Our team is a mix of medical and IT professionals. There are 2 trauma surgeons, with daily hands-on experience in the operating theatre, and involved in the current ordering process of implants. Our IT professional has vast experience in managing IT projects with specialization in 3D, medical applications, artificial intelligence. A medical engineer who joined the team later on has previously developed and patented a unique bone implant. # Dicronis twitter.com/dicronis linkedin.com/company/dicronis Lymphedema is a chronic and progressive condition, often resulting in high debilitation of the patients suffering from it. It manifests with a restrained to extensive swelling of a limb. This occurs because, in the context of the cancer treatment, lymph nodes have been removed, as metastatic cancer cells have been found there. When this happens, the lymphatic system gets disrupted and does not function properly anymore. Nevertheless, current diagnostic products/ methods focus on the measure of the extent of fluid accumulation over time, i.e. the symptomatic manifestation of the disease rather than its causality. This results in a delayed diagnosis which further complicates management of lymphedema, as only conservative treatments are available, i.e. treatments that avoid a worsening of the disease but are not able to treat it. The scientific community agrees to the need of an earlier diagnosis, ideally in the subclinical stage, when the lymphatics are impaired but fluids have not accumulated yet. At Dicronis, we are developing the first home-based and highly-scalable lymphatic activity tracker, referred to as Lymphit. We allow this through our patented technology comprising a microneedles patch for delivery of a fluorescent agent, and monitoring of its disappearance rate from the skin via a wearable detector. Sharing the data with the treating physician will ensure the best monitoring. Owing to its ease-of-use and painless delivery, it is a home-based solution, carrying the advantage of a more frequent disease monitoring and therefore better management. # Dipl. Math. Alex Babanin, CEO at Insuma GmbH and Avalanche GbR alex.babanin@gmail.com Patrizia Marschalkova patrizia@dicronis.com 30 31

17 Germany EARLIEBIRDIE KORMORAN11 is an innovative patented product which can improve men s health supporting active ageing by simple self testing of uroflow at home. It mainly addresses men who prefer testing in privacy first - before consulting a specialist. An uroflow below a certain threshold* is a signal for a potential prostate and/or bladder modification. In Europe ca. 60% of the 60 million men in the age of over 60 years show an enlarged prostate. Men above 80 years of age already have a 90% probability of an enlarged prostate**. KORMORAN11 has been co-developed by EARLIEBIRDIE, a Bavarian start-up company, together with Digmesa AG, a Swiss precision flowmeter specialist. The development was granted by Bayern Innovativ. Prof. Dr. med. L. Weißbach, a leading expert urologist in the field, was the medical consultant of this project. Next milestones will be the testing of the KORMORAN11 prototype in a use study conducted in selected European urological centers, followed by a certification of the device by an already identified expert in this field till spring *Threshold due to European medical guidelines. In this case it is 11 ml/sec Qmax (sensor adjustable) **Eurostatistics ec.europa.eu, Bundesministerium für Familie, Senioren, Frauen und Jugend bmfsfj.de, medical guidelines for benign prostate hyperplasia (BPH) # FeelSpace twitter.com/feelspacebelt feelspace develops makes orientation easy for everyone. Being able to navigate easily belongs to the basic requirements for an independent lifestyle and a self-determined leisure time. Especially blind people are disadvantaged in our visually dependent navigation world, and need help in their daily life to reach the places they want to visit. One major problem with current solutions, such as GPS-based navigation apps for smartphones, is that users always have to listen to the navigational information, interfering with their ability to attend to the closer environment and traffic. The feelspace GmbH developed a navigation belt to improve orientation for visually impaired people, for whom a tactile navigation device greatly improves the feasibility to participate in working and social life. Our belts use 16 vibration elements, distributed equidistantly around the waist, to continuously output directional information that the user feels around the waist. This keeps your eyes, ears and hands free during navigation. While the belt is particularly useful for the blind and visually impaired, it is also of great use e.g. for seniors or outdoor sports. Our tactile belt is the first such product on the market. Due to the strong scientific background of the founding team from the University of Osnabrück and the resulting close links to the latest research, our team is well qualified for the development of customized innovative solutions. By now we already established an extensive network in the blind market and had recently the first belt fully financed through a health insurance. # Simone Gschaidmeier info@earliebirdie.de Susan Wache, CMO and founder susan.wache@feelspace.de 32 33

18 Germany Heyfair Every year, 2.6 million Europeans get an infection during their hospital stay. About patients don t survive. The best measure to prevent these deaths is the hand disinfection. But even schooled professionals make common mistakes that render disinfections ineffective or they forget it completely. To solve these problems Heyfair has invented the world s first shortly visible disinfectant. By dying the hands for about three minutes gaps can be easily avoided and the germicidal efficacy easily controlled. By making hygiene visible disinfections also happen more conscientious in general. This way patients are safe. # HygNova twitter.com/hygnova HygNova COMPLETE helps hospitals and nursing homes tackling their nosocomial infections by gapless visualization of the hand disinfection rate at the point-of-care and accumulation of gathered information in cloud-based data dashboards. The lack of hygiene is a global problem, even in developed countries. In Germany alone, they`re over hospital infections and estimated deaths per year causing a financial burden of BN 1,6. The European Union spends more than BN 5 per year for hospital infections and the problems that come with them. HygNova helps in the avoidance of healthcare associated infections (HAIs) by increasing the hand disinfection rate of staff on the long-term. For nursing homes and hospitals, HygNova is developing a technical device to monitor all the relevant moments for hand hygiene, to remind in the right situations to sanitize and to add value to the work of personnel by implementing gamification and other behavioral change interventions. The goal is to keep the hand disinfection rate high and to protect the mainly aged population to remain healthy. By improving the quality of care on the bedside and through better data knowledge, especially ageing populations can remain independent and stay integrated in society. In HygNova COMPLETE, IoT-sensor technique is used and paired with behavioral change theory. The glue for all components of HygNovas technology is ICT, which allows the immediate and permanent availability of specific knowledge and the opportunity for appropriate action. # Robert Hellmundt, Founder & CEO robert.hellmundt@heyfair.de Simon Slama CTO scs@hygnova.com 34 35

19 Germany Ichó facebook.com/ichosystems instagram.com/icho.systems twitter.com/icho_systems vimeo.com/ichosystems Every 3 seconds, someone in the world develops dementia. Germany has the oldest society in Europe and the second-oldest in the world. Today, healthcare systems are working at their limits and are prognosticated to collapse by the year 2050, if no innovations are developed. ichó tries to be part of the solution by deferring the need for inpatient care through targeted cognitive and motoric training. ichó is a ball that reacts to outside influences like pressure, catching, stroking, and throwing. ichó reacts with signals such as coloured light, vibration, music, and sounds, all aiming to promote the user s motor skills and cognitive function. The individual support targeted for each user makes ichó exceptional. ichó can be quickly modified through a mobile app no matter where the user or facilitator is. This allows each user to have an entirely new, playful, and individual experience during therapy. With ichó relatives and affected can find a playful access to each other. Regular games promote the cognitive and motoric skills of the user, thus helps to keep everyday skill and slow the disease progression. In use during the nursing daily life, ichó can perform routine actions easier, because the users are more sociable and relaxed. This relaxes also caregivers and nurses. # inveox twitter.com/inveox Pathology inveox digitizes, streamlines and automates pathology laboratories. As a result, the safety and reliability of cancer diagnoses are enhanced, while increasing the efficiency and profitability of laboratories. Time-intense, highly manual and error-prone lab processes are expensive and the most common reason for cancer misdiagnoses. Irregularities in approximately 1-15% of all cases nowadays can lead to wrong positive/negative lab diagnoses which, worst case, result in misdiagnoses or mistreatments. That s why inveox digitizes, streamlines and automates pathology laboratories to make cancer diagnoses safer and labs more efficient. Therefore, the inveox team has developed an automation system consisting of three components: a data and communication platform which securely connects physicians and pathology labs end-to-end, connecting patient data with a unique specimen ID proprietary biopsy containers with integrated filters for automated sample handling and an innovative automation machine for sample entry, including touch-free formalin disposal, a visual ID unit and AI based image recognition In 2018, barely one year after founding, inveox presents the world s first automation system for encapsulating biopsies. # Mr. Steffen Preuß, CEO preuss@icho-systems.de Maria Driesel, Founder and CEO maria.driesel@inveox.com 36 37

20 Germany IT-labs twitter.com/itlabs fb.me/halloalberta We are developing an intelligent therapymanagement platform for all providers of the chronically ill patients. Our software is designed to interconnect all employees in the field of medical services, doctors, hospitals, nursing homes and services more closely. This will make processes more efficient and easier to ultimately increase the quality of life of patients. With our innovative software Alberta, we improve healthcare by suggesting the field care staff of homecare companies the right products for each patient s medical conditions. Today, the registered nurse (sales representative) decides purely on her gut feeling and what she has learned. Our software calculates the supply range when ordering and reminds the user when the next order is due or even when the next visit is due. As a result, no patient gets lost in the stress of everyday life and the level of stress on employees drops to a minimum. Mr. Güven Karakuzu, Founder and CEO g.karakuzu@it-labs.de Aberta includes: patient equipment, findings documentation, health care proposal, order and recipe management, recipe reconciliation, mission and trip planning, CRM capabilities, team management and a so-called Cloud-Akte. With this we map the complete supply process in one application. In addition, the therapy course of the patient can be tracked. The patient data is transmitted with interfaces to the ERP system and can then be settled with the payers. # LARALAB LARALAB develops image-based software technology to support heart teams with procedural planning and pivotal guidance of heart interventions, especially emerging minimally-invasive heart valve repair procedures. It s the first software to automatically analyze the varying anatomical structures of each patient based on multi-model images while deep learning algorithms determine optimized access routes and best-suitable instruments. The results then will be visualized and the decision-making for the cardiologist of which procedure to choose will be greatly faster and more efficient. The breakthrough of procedures like TMVR (Transcatheter Mitral Valve Replacement) Boris Link, Product Management boris.link@laralab.de Julian Praceus, Founder and CEO and TTVR (Transcatheter Tricuspid Valve Replacement) is imminent and patient-individual advanced software planning helps conduct them safer which is our initial focus. # 38 39

21 Germany LegaGene Dyslexia is a severe disorder in the acquisition of reading and writing with a prevalence of about 5%. It has a strong biological background and a heritability of up to 70%. It is a complex disease, i.e. a large number of genetic variants contribute to the risk instead of just a single gene. Main problem in dyslexia is the late diagnosis at the end of the 2nd grade, resulting in years of lost time for early intervention. An early test based on biological markers could solve this problem. In the recent years, a consortium of Fraunhofer IZI and partners started to develop a multimodal dyslexia screening test on the basis of genetics and neurophysiological markers. During this project the Fraunhofer IZI, could create a list of 25 potential genetic dyslexia markers to be used in the current project. The fastest and most economical way to analyze these markers in the final test is a genetic test panel containing all markers of interest to allow a multiplex analysis for all markers at the same time. Dr. Arndt Wilcke, Team Leader Cognitive Genetics Department of Cell Therapy, Cognitive Genetics Fraunhofer Institute for Cell Therapy and Immunology arndt.wilcke@izi.fraunhofer.de Dr. Anna C. Eichhorn, Vorstand/CEO humatrix AG anna.eichhorn@humatrix.de This project aims to develop such an array. Therefore, this project lays the practical foundation for a successful market entry of the humatrix AG as Germany s first provider of an early genetic test for dyslexia. # MUNEVO MUNEVO s vision is to help people with disabilities by using new and innovative technology. MUNEVO DRIVE is the first wheelchair control using smart glass technology. Claudiu Leverenz claudiu@munevo.com twitter.com/glasschairde # 40 41

22 Germany nanoleq GmbH At nanoleq GmbH (ETH Zurich spin-off, our ambition is to provide the next generation of highly reliable cables to the market. Electrical cables are fragile and often prone to breakage due to repeated mechanical stress, which leads to complete failure of the electronic devices they are used for. This is particularly an issue in a large variety of body-worn medical devices, hospital equipment and electrical implants. In some critical devices, cable failure may have serious consequences or even be life-threatening. Based on (i) a new cable architecture and (ii) the use of innovative stretchable & conductive materials developed in our research labs, our cable technology shows a highly improved flex lifetime (improvement up to a factor x100 compared to standard cables). With our newly developed cable solution, we aim at greatly improving the reliability of electrical cabling in critical healthcare systems. # NovoScreen NovoScreen: State-of-the-art cervical cancer screening from home. Private. Convenient. Simple. Although being mostly preventable via screening, cervical cancer is the 4th most common cancer in women worldwide. The current screening paradigm is based on a vaginal exam by a gynecologist, which is perceived as intrusive and embarrassing by many women. In addition, such screening is inconvenient since women need to take time off work or childcare. As a result, screening participation is well below 70% in most countries, and many women do not even have access to a screening programme. NovoScreen is a simple and user-friendly self-sampling pen that enables women to collect a smear sample conveniently from home. It will make screening more acceptable, more accessible, and more convenient, and will help increase screening participation in women who cannot be reached by physician-based screening. These are often women at high risk for cervical cancer. NovoScreen is the first self-sampling method that features the same test methods as physician-based sample taking in many high income countries (cytology in combination with HPV testing). The sample obtained can also be tested for sexually transmitted infections such as chlamydia or gonorrhea. NovoScreen thus empowers women to take care of their own gynecological health privately from home, at their own time and pace. It is our vision to make cervical cancer screening accessible to all women, to help prevent cervical cancer, and to reduce treatment-related morbidity and cost. Our awareness campaigns will help increase knowledge on this sensitive, but important and often life-saving topic. # Vincent Martinez, CEO martinez@nanoleq.com Michaela Fesenfeld michaela.fesenfeld@novoscreen.com 42 43

23 Germany ScintHealth ScintHealth offers a new therapy for solid tumors that are hard or impossible to operate. In those cases to reduce side-effects, the therapy of choice is chemotherapy in combination with local treatments such as embolization and ablation. However, the success of this approach is limited by the impossibility to plan the treatment, the need for large security margins and the lack of interventional control. By precise treatment disease-free survival and quality of life can be significantly prolonged, resulting in better quality of life, cost reductions and an overall improved healthcare. ScintHealth s product CelluRad is a beta-emitting radioactive polymer that when injected into a lesion solidifies immediately enabling a precise and highly effective local treatment with minimal side effects. ScintHealth also provides a high-tech fully integrated image-guided injection system using thin bent needles and planning software capable of injecting CelluRad in almost any shaped and sized lesion through a single stich and having direct control of the procedure at all times. CelluRad targets initially the market of inoperable and hard to operate liver tumors, estimated to be > new cases per year in Europe. Current disease-free survival for those treatments is only in the range of 3-9 months and mortality is >90%, while costs are as high as /treatment. With a pay-per-use model, a wise selection of the radioisotope and a thin but robust supply chain, ScintHealth sinks costs and simplifies clinical workflow and logistics while giving patients a longer and more pleasant life. # Sleepiz AG Sleepiz AG is a Zurich based award-winning Med-tech start-up founded by graduates from ETH Zurich and the University of St. Gallen (HSG), backed by leading sleep specialists in Switzerland. 30% of the world population suffers from sleep disorders. Sleep apnea is the most serious sleep disorder whereby one stops breathing frequently while asleep, it has a global prevalence of 1 billion - yet more than 80% of these cases are not diagnosed! If left untreated, it doubles the risk for sudden cardiac death, stroke, increases the risk for cardiovascular mortality fivefold, and leads to dementia, traffic accidents, and productivity losses. The current healthcare system is not equipped to handle such an influx of cases due to outdated screening and diagnosis technologies. For example, the state of the art requires overnight hospitalization, full-time supervision by a technician, and the attachment of more than 30 cables. As a result, doctors incur a huge time and cost burden in conducting such tests and are looking for more efficient screening solutions without having to compromise for data accuracy and reliability. Sleepiz has developed a revolutionary sleep disorder screening device. By using wireless technology, the device can measure human vital signs at medical accuracy without touching the patient - enabling non-contact clinical grade home diagnosis of sleep apnea. To date Sleepiz has proven the technology in a clinical context and is currently in the process of obtaining the necessary medical approvals. Please contact Sleepiz for more information and support next generation home-diagnostics! # Dr. Thomas Wendler thomas.wendler@scinthealth.com Mr. Max Sieghold, Co-Founder and Chief Financial Officer (CFO) max.sieghold@sleepiz.com 44 45

24 Germany THE JURY / JUDGES Biography: Jan is a Managing Director with EMBL Ventures, focusing on opportunities in the drug development sector. He has been representing the firm on various portfolio boards, e.g., Lipid Therapeutics, Opsona, Arsanis and ViraTherapeutics. Prior to joining EMBL Ventures, Jan was a postdoctoral Fellow of the Ernst Schering Research Foundation at the University of Granada, Spain. Before Jan Adams Company: EMBL Ventures Job title: Managing Director that he was a Fellow of the Boehringer Ingelheim Research Foundation, conducting work on molecular transport mechanisms at the Wellcome CRC in Cambridge, UK. Jan holds a M.S. in Biochemistry & Molecular Biology from Tübingen University, Germany and completed a PhD in Genetics at the University of Cambridge, UK

25 Germany Biography: Thomas Hegendörfer Company: Johnson & Johnson Innovation Job title: New Ventures Lead, Germany Thomas Hegendörfer is the New Ventures Lead in Germany for Johnson & Johnson Innovation. He is responsible for identifying collaboration opportunities and forging partnerships between the London Innovation Centre and German innovators and entrepreneurs. Before joining Johnson & Johnson, Thomas was Head of Business Development at Lead Discovery Center GmbH (LDC), a leading translational center in Germany advancing academic drug discovery into application. He held this position for 9 years. Prior to joining the LDC he worked as a Project Manager in Licensing and Patent Management at Max Planck s technology transfer agency Max Planck Innovation. Thomas was part of the core team at Max Planck that set up a Transitional Drug Discovery Centre, which finally developed into the LDC. Biography: Dr. Torsten Niederdränk Company: Siemens Healthcare GmbH Job title: Head Technology & Innovation Center Torsten Niederdränk is Head of the Siemens Healthineers Technology Center in Erlangen, Germany. Main tasks are to develop, access & commercialize new technologies and approaches. The Technology Center is running basic / applied research projects for innovations across business lines and in white spaces. After managing the global R+D and Supply Chain functions at Siemens Audiology until 2008 and heading an internal Siemens Research & Consulting Unit, from 2014 he was involved in shaping the new Siemens Healthineers strategy as Corporate Strategy Officer at Siemens Healthcare GmbH. Torsten Niederdränk received the Lothar-Cremer-Award of the European Acoustics Association for his contributions in Acoustic Cavitation He became Siemens Inventor of the Year 2004, received the Siemens Medical Solutions Innovation Award 2005 and the Future Award of the President of the Federal Republic of Germany 2012 for the first binaural Hearing System

26 Germany Biography: Néstor Rodríguez Company: Atrineo AG Job title: Co-Founder and Managing Director Néstor Rodríguez Co-Founder and Managing Director of Atrineo AG, holds a degree in cybernetics engineering from the University of Stuttgart and has been working as an international consultant for over 15 years. Néstor Rodríguez has over 15 years of experience in the commercialisation of technologies both from academia and the private sector. With a background in Private Equity and Corporate Strategy, both internally at Siemens and as an external strategy consultant, Néstor s core competency is in identifying, evaluating, developing and implementing business models for novel technologies. He has led and managed 100s of international market research projects both for corporates and hightech start-up companies and regularly provides seminars and workshops on market and market research to young entrepreneurs in German academia and research institutions. Néstor has helped set-up, structure and finance over 30 start-up companies at the very early growth stage. He is currently an international business coach for the European EASME agency for innovative SMEs. Biography: Veronika Schweighart Company: Climedo Health GmbH Job title: Co-Founder & COO Veronika Schweighart studied Business Administration at the LMU in Munich and Technology Management at the Center for Digital Technology and Management (CDTM). She has international work experience in business development, consulting and marketing and co-founded her first startup, Nuclino, directly after her studies. Since 2017, she is Co-Founder & COO of Climedo Health, a digital assistant for doctors to accelerate the introduction of personalized cancer therapies

27 Germany Biography: Dr. Therese Tönnies Therese holds a PhD in Experimental Psychology, Neuropsychology & Human Machine Interaction and started her carrier as a UX consultant for Siemens Healthcare. In 2016 she left the Company: Qolware GmbH Job title: Managing Director corporate world to cofound Qolware, a health-tech startup which uses wearable technologies to support elderly and chronic patients in handling emergency situations and monitor health changes. Dr. Michael Ullmann, MD MBA Biography: Company: Johnson & Johnson Medical Devices Companies Job title: Director Medical & Clinical Affairs Cardiovascular & Specialty Solutions (CSS) EMEA Before joining Johnson & Johnson in October 2017, Michael was the Chief Medical Expert at Robert Bosch GmbH Stuttgart from January 2012 to September 2017, where he jointly headed the Strategic Project Program Healthcare Solutions within Corporate Research and Advance Engineering. During this time, he scouted emerging medical topics and reported to researchers and top-management on a regular basis. As a specialist in general & sports medicine, Michael run his own practice for about six years in Karlsruhe, Germany, before he joined Bosch. In addition, he is a former surgeon with a specialist level in cardiac surgery and two years of general surgery (visceral, trauma, pediatric, and vascular surgery). His interdisciplinary clinical research on flow-induced pulmonary hypertension at the University of Heidelberg was funded by a grant of the German Heart Foundation

28 ABOUT EIT HEALTH EIT Health

29 EIT Health One of the largest Healthcare Initiatives Worldwide A unique European Network International Headquarters in Munich Our goal is to sustainably advance the foundations of healthcare and thus promote the future conditions for healthier living and wellbeing of people across Europe. EIT Health does this by leveraging the expertise of more than 140 leading organisations spanning key areas of healthcare such as Pharma,, Payers, Research Institutions and Universities. With a budget EIT Health Germany of 2 billion EUR over the next decade, EIT Health will purposefully invest in Europe s best entrepreneurial talents and creative minds to foster the development and commercialisation of smart product and service solutions in the health sector, addressing the challenges imposed by demographic change and ageing societies. 6 Co-Location Centres (CLCs): UK-Ireland (London) Scandinavia (Stockholm) Belgium-Netherlands (Rotterdam) Germany-Switzerland (Mannheim/Heidelberg) France (Paris) Spain (Barcelona) 7 InnoStars regions: (in 6 countries) Croatia Hungary Poland Portugal Italy Wales EIT Health Germany supports 28 partners from various sectors (eg. pharma, medtech, IT, diagnostics, research, education and others) in Germany and Switzerland in developing innovative healthcare solutions for current and future challenges. Core Partners Associate Partners 56 57

30 58 59